25. Deferred income
The movement in the non-current and current deferred income is detailed in the table below.
(thousands of €) |
Total |
Gilead collaboration agreement for filgotinib |
Gilead collaboration agreement for drug discovery platform(1) |
Deferred income related to contracts in our fee-for-service segment |
Other deferred income (grants) |
||||
|---|---|---|---|---|---|---|---|---|---|
On 1 January 2020 |
3,000,646 |
780,261 |
2,220,013 |
362 |
10 |
||||
|
|
|
|
|
|
||||
Upfront consideration |
160,000 |
160,000 |
|
|
|
||||
Milestones received |
90,192 |
90,192 |
|
|
|
||||
Significant financing component(2) |
16,278 |
16,278 |
|
|
|
||||
|
|
|
|
|
|
||||
Revenue recognition of upfront |
(411,417) |
(181,816) |
(229,601) |
|
|
||||
Revenue recognition of milestones |
(46,261) |
(46,261) |
|
|
|
||||
|
|
|
|
|
|
||||
Other movements |
(305) |
|
|
(362) |
57 |
||||
|
|
|
|
|
|
||||
On 31 December 2020 |
2,809,133 |
818,654 |
1,990,412 |
- |
67 |
||||
|
|
|
|
|
|
||||
|
|
|
|
|
|
||||
Upfront consideration |
12,643 |
12,643 |
|
|
|
||||
Significant financing component(2) |
9,289 |
9,289 |
|
|
|
||||
|
|
|
|
|
|
||||
Revenue recognition of upfront |
(433,884) |
(203,301) |
(230,582) |
|
|
||||
Revenue recognition of milestones |
(32,408) |
(32,408) |
|
|
|
||||
|
|
|
|
|
|
||||
Other movements |
(67) |
|
|
|
(67) |
||||
|
|
|
|
|
|
||||
On 31 December 2021 |
2,364,701 |
604,875 |
1,759,828 |
- |
- |
||||
|
|||||||||
We refer to note 6 for a detail of the allocation of the transaction price of our collaboration with Gilead.